Navigation Links
BeneChill Raises $13.5 Million Series C
Date:7/20/2009

SAN DIEGO, July 20 /PRNewswire/ -- BeneChill (www.benechill.com) - a privately held medical device company that concentrates on developing products in the therapeutic hypothermia arena with a focus on rapid, non-invasive cooling for use in the field - today announced it has closed a $13.5 million Series C financing. New investor HealthCap (Stockholm) led the financing. Series A and B investors MedVenture Associates, NGN Capital, and the Solon Foundation also participated. Proceeds will be used to fund early commercialization of the company's RhinoChill device.

Concurrent with the Series C financing, Johan Christenson of HealthCap joined the BeneChill Board of Directors.

BeneChill has recently completed its randomized PRINCE (Pre-Resuscitation Intra-Nasal Cooling Effectiveness) study of the RhinoChill device in cardiac arrest patients. This study will determine whether the addition of intra-nasal cooling during resuscitation improves outcome following cardiac arrest over hospital-based cooling alone. Results of the PRINCE trial will be announced at the American Heart Association's Scientific Sessions in Orlando, Florida in November, 2009.

About the RhinoChill device

The RhinoChill device is non-invasive, portable, easy-to-use and does not require an external source of power for cooling. The device consists of a nasal catheter which delivers a proprietary inert coolant to the nasopharynx in patients requiring hypothermia. Hypothermia is currently used in patients with cardiac arrest, stroke or head injury. Unlike other cooling devices, the RhinoChill device is easily utilized in emergency field settings. The RhinoChill System is an investigational device in the United States, and is limited by US law to investigational use only. The company received a CE Mark for the RhinoChill device in 2007.

About BeneChill

BeneChill is a venture capital funded medical device company based in San Diego, CA. The company is developing products in the therapeutic hypothermia arena with a focus on rapid, non-invasive cooling for use in the field.


'/>"/>
SOURCE BeneChill
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BeneChill Launches European Study of Intra-Arrest Cooling
2. BeneChills RhinoChill System Receives CE Marking for European Commercial Sale
3. National Advocacy Organization Representing Home Oxygen Patients Praises Introduction of Medicare Home Oxygen Therapy Act
4. American Chemical Society praises nomination of Collins as NIH Director
5. Stem Cell Industry Expert Praises, Encourages Continued Progress on Legislation to Promote Benefits of Cord Blood
6. Lung Cancer Alliance Praises Congresswoman Donna Christensen for Introduction of Legislation to Correct Healthcare Disparities
7. Hyperion Therapeutics Raises $60 Million Series C
8. Cytox Raises Pre-Series A Financing From Management and Existing UK Investors, Welcomes First US Investors
9. Obesity Greatly Raises Endometrial Cancer Risk
10. Transcend Medical Raises $35 Million Series B Round Towards Development of Novel Glaucoma Treatment
11. EUROPACE raises remote monitoring profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... ... "I have gout, and I wanted to treat it naturally," said an ... relieve gout and pain caused by varicose veins. I drank it every morning for ... what VA doctors called the worst sinusitis case they'd seen and relieved gas, stress ...
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, the ... the grand opening of the Sober College Robert Pfeifer Memorial Learning Center at ... 2-3, and was attended by an overwhelming amount of alumni, family, colleagues and ...
(Date:12/9/2016)... ... December 09, 2016 , ... Mediaplanet today announces distribution of the latest edition ... to sign up as an organ donor for the 123,000 people in the United ... donor can save up to 8 saves through organ donation and enhance many others ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... whiteboard display solutions, proudly announced today that a new solution for Emergency Departments ... fit in the tight space in Emergency Department examination rooms, and with a ...
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Cable Network (PCN) during the summer of 2016. The program was made possible ... the United States Department of Health and Human Services Administration. The broadcast, ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Mitsubishi Tanabe Pharma Corporation (Head Office: ... Dr. Masayuki Mitsuka ) has presented data that ... intravenously in 10-14 day cycles for 48 weeks experienced ... Functional Rating Scale-Revised (ALSFRS-R). The data were presented at ... Dublin, Ireland . In ...
(Date:12/9/2016)... , Dec 9, 2016 Research and Markets ... 2016-2020" report to their offering. ... The global travel vaccines market to grow ... The report covers the present scenario and the growth prospects of ... size, the report considers the revenue generated from the sales of ...
(Date:12/9/2016)...  Forge Therapeutics, Inc. today announced a strategic ... TecDAX, ISIN: DE0005664809) to advance its novel Gram-negative ... bacterial infections including those caused by drug resistant ... antibacterial target for more than the past 15 ... points has hampered its progress. Forge has been ...
Breaking Medicine Technology: